The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Of late, the company has been fast gaining momentum, leveraging consistent upgrades of FreeStyle Libre. In 2024, Abbott obtained FDA approvals for two new over-the-counter continuous glucose ...

Abbott’s FreeStyle Libre CGM system has become a pivotal growth catalyst, particularly after starting collaborations with Medtronic (MDT) last summer and Epic two months ago.

Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion July 02, 2025 — 10:01 am EDT Written by Zacks Equity Research for Zacks -> ...

Per the Zacks Consensus Estimate, the company’s revenues for 2025 are expected to increase 10.6%. More on t:slim X2’s Compatibility With FreeStyle Libre 3 Plus ...

SAN DIEGO, June 20, 2025--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ ...

Abbott’s ABT diversified business portfolio appears to be well-positioned to drive continued momentum in 2025. The stock carries a Zacks Rank #2 (Buy) currently. Factors Driving ABT Shares Within ...

The FreeStyle Libre 3 Plus sensor has an extended 15-day wear time, transmitting automatic glucose readings every minute directly to the pump. This data is also available to view on the Tandem t:slim ...

Coca-Cola Freestyle offers 100 different flavors of soda to enjoy on their own or mix and match into endless combinations.

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via the NHS to eligible people with diabetes in the UK. Abbott's wearable FreeStyle Libre 3 device ...